Zevra Therapeutics Appoints New CFO to Drive Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 05 2026
0mins
Should l Buy ZVRA?
Source: NASDAQ.COM
Zevra Therapeutics' stock surged by 21.27% as it crossed above the 5-day SMA, reflecting strong investor interest following the announcement of Justin Renz as the new CFO.
The appointment of Justin Renz, who brings over 25 years of financial leadership experience in the biopharmaceutical industry, is expected to enhance Zevra's strategic plan and market position in rare diseases. His previous roles included significant contributions to the launch and commercialization of innovative medicines, which will support Zevra's financial foundation and growth trajectory.
This leadership change is likely to instill confidence among investors, as Renz's extensive experience in capital markets and strategic transactions positions Zevra for future success in the competitive rare disease market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZVRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZVRA
Wall Street analysts forecast ZVRA stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 11.130
Low
21.00
Averages
24.00
High
26.00
Current: 11.130
Low
21.00
Averages
24.00
High
26.00
About ZVRA
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zevra Therapeutics Reports Q1 2026 Earnings with Strong Growth Indicators
- Significant Revenue Growth: Zevra Therapeutics reported net revenue of $36.2 million in Q1 2026, with $24.6 million from MIPLYFFA sales in the U.S., indicating strong performance in the rare disease market and potential for increased market share moving forward.
- Asset Optimization and Debt Clearance: The company divested its SDX portfolio to Commave Therapeutics for $50 million and successfully retired its debt early, marking Zevra as debt-free, which enhances financial flexibility for future strategic investments.
- Expanded Patient Access Program: As of Q1 2026, Zevra's global Expanded Access Program (EAP) has enrolled 122 patients, up from 113 at the end of 2025, indicating positive progress in improving patient treatment accessibility.
- Diversified Clinical Development Pathways: Zevra is actively preparing for follow-up meetings with the FDA to accelerate clinical development and plans to boost MIPLYFFA enrollment through multiple pathways, demonstrating the company's responsiveness to market demands and adaptability.
See More
Zevra (ZVRA) Q1 2026 Earnings Call Transcript
See More
Zevra Therapeutics to Report Q1 Financial Results on May 6, 2026
- Earnings Announcement: Zevra Therapeutics will report its first-quarter financial results on May 6, 2026, after market close, followed by a conference call at 4:30 PM ET, highlighting the company's advancements in rare disease therapies.
- Investor Relations Access: Investors can access the audio webcast via the 'Events & Presentations' page on Zevra's website, ensuring transparent communication and information dissemination with stakeholders.
- Market Validation: The commercialization of Zevra's lead product for Niemann-Pick disease type C in the U.S. validates the company's capability to transition therapies from development to market, establishing a solid foundation for future product line expansion.
- Strategic Vision: Zevra is committed to enhancing access to therapies for rare disease patients through geographic expansion and progress toward key milestones, reflecting the company's patient-centric strategic vision and core values.
See More
Zevra Therapeutics Surges 21% After Strong Earnings Report
- Strong Earnings: Zevra Therapeutics reported over $34 million in net revenue for Q4 2025, a 44% increase year-over-year, significantly exceeding analysts' expectations of $28 million, indicating robust market performance and growth potential.
- Profit Turnaround: The company achieved a GAAP net profit of $12.2 million ($0.19 per share), a remarkable turnaround from a $35.7 million loss in the previous year, enhancing investor confidence in its financial health.
- Miplyffa Sales Surge: Miplyffa's net sales skyrocketed to over $87 million in the quarter, nearly ninefold growth compared to last year, reflecting strong market acceptance for treating Niemann-Pick disease and driving overall company performance.
- International Market Potential: Zevra has filed a marketing authorization application for Miplyffa with the European Medicines Agency, indicating significant expansion potential in international markets, which could further bolster the company's growth trajectory.
See More
Zevra Therapeutics Reports 44% Revenue Growth and Profitability
- Financial Performance Exceeds Expectations: Zevra Therapeutics reported over $34 million in net revenue for Q4, reflecting a 44% year-over-year increase that significantly surpassed analyst expectations of $28 million, indicating robust market performance and a notable improvement in profitability.
- Profit Turnaround: The company achieved a GAAP net profit of $12.2 million ($0.19 per share), a substantial turnaround from a loss of $35.7 million in the same quarter last year, which enhances investor confidence in the company's financial health.
- Miplyffa Drug Success: Miplyffa's net sales soared to nearly $87 million this quarter, nearly ninefold growth compared to last year, with coverage reaching 68% of lives, demonstrating strong market acceptance and potential in treating Niemann-Pick disease.
- International Market Opportunities: Zevra has filed a marketing authorization application for Miplyffa with the European Medicines Agency, indicating that the drug's success in the U.S. could be replicated in the European market, further expanding the company's growth prospects.
See More
GeneDx Partners with Zevra to Enhance NPC Diagnosis and Treatment
- Genetic Testing Collaboration: GeneDx has partnered with Zevra Therapeutics to launch the ExomeDx genetic testing program aimed at expanding access for suspected Niemann-Pick disease type C patients, thereby accelerating clinical diagnosis and improving accuracy.
- Data-Driven Innovation: By leveraging the GeneDx Infinity dataset, the world's largest rare disease genomic dataset, partners can gain deeper insights into disease biology, thus accelerating the patient journey from diagnosis to treatment, showcasing the real-world impact of genomic insights.
- Strong Financial Performance: Zevra Therapeutics reported fourth-quarter earnings of $0.19 per share, exceeding analyst expectations of $0.05, with sales totaling $34.1 million, surpassing estimates of $28.1 million, indicating robust growth potential in the Niemann-Pick disease treatment sector.
- Strategic Shift: Zevra has relocated its global headquarters to Boston to better access specialized talent and plans to focus on multiple near-term growth opportunities in 2026, aiming to create greater value for the rare disease community and its shareholders.
See More
Zevra Therapeutics Reports Q1 2026 Earnings with Strong Growth Indicators
- Significant Revenue Growth: Zevra Therapeutics reported net revenue of $36.2 million in Q1 2026, with $24.6 million from MIPLYFFA sales in the U.S., indicating strong performance in the rare disease market and potential for increased market share moving forward.
- Asset Optimization and Debt Clearance: The company divested its SDX portfolio to Commave Therapeutics for $50 million and successfully retired its debt early, marking Zevra as debt-free, which enhances financial flexibility for future strategic investments.
- Expanded Patient Access Program: As of Q1 2026, Zevra's global Expanded Access Program (EAP) has enrolled 122 patients, up from 113 at the end of 2025, indicating positive progress in improving patient treatment accessibility.
- Diversified Clinical Development Pathways: Zevra is actively preparing for follow-up meetings with the FDA to accelerate clinical development and plans to boost MIPLYFFA enrollment through multiple pathways, demonstrating the company's responsiveness to market demands and adaptability.
See More
Zevra (ZVRA) Q1 2026 Earnings Call Transcript
See More
Zevra Therapeutics to Report Q1 Financial Results on May 6, 2026
- Earnings Announcement: Zevra Therapeutics will report its first-quarter financial results on May 6, 2026, after market close, followed by a conference call at 4:30 PM ET, highlighting the company's advancements in rare disease therapies.
- Investor Relations Access: Investors can access the audio webcast via the 'Events & Presentations' page on Zevra's website, ensuring transparent communication and information dissemination with stakeholders.
- Market Validation: The commercialization of Zevra's lead product for Niemann-Pick disease type C in the U.S. validates the company's capability to transition therapies from development to market, establishing a solid foundation for future product line expansion.
- Strategic Vision: Zevra is committed to enhancing access to therapies for rare disease patients through geographic expansion and progress toward key milestones, reflecting the company's patient-centric strategic vision and core values.
See More
Zevra Therapeutics Surges 21% After Strong Earnings Report
- Strong Earnings: Zevra Therapeutics reported over $34 million in net revenue for Q4 2025, a 44% increase year-over-year, significantly exceeding analysts' expectations of $28 million, indicating robust market performance and growth potential.
- Profit Turnaround: The company achieved a GAAP net profit of $12.2 million ($0.19 per share), a remarkable turnaround from a $35.7 million loss in the previous year, enhancing investor confidence in its financial health.
- Miplyffa Sales Surge: Miplyffa's net sales skyrocketed to over $87 million in the quarter, nearly ninefold growth compared to last year, reflecting strong market acceptance for treating Niemann-Pick disease and driving overall company performance.
- International Market Potential: Zevra has filed a marketing authorization application for Miplyffa with the European Medicines Agency, indicating significant expansion potential in international markets, which could further bolster the company's growth trajectory.
See More
Zevra Therapeutics Reports 44% Revenue Growth and Profitability
- Financial Performance Exceeds Expectations: Zevra Therapeutics reported over $34 million in net revenue for Q4, reflecting a 44% year-over-year increase that significantly surpassed analyst expectations of $28 million, indicating robust market performance and a notable improvement in profitability.
- Profit Turnaround: The company achieved a GAAP net profit of $12.2 million ($0.19 per share), a substantial turnaround from a loss of $35.7 million in the same quarter last year, which enhances investor confidence in the company's financial health.
- Miplyffa Drug Success: Miplyffa's net sales soared to nearly $87 million this quarter, nearly ninefold growth compared to last year, with coverage reaching 68% of lives, demonstrating strong market acceptance and potential in treating Niemann-Pick disease.
- International Market Opportunities: Zevra has filed a marketing authorization application for Miplyffa with the European Medicines Agency, indicating that the drug's success in the U.S. could be replicated in the European market, further expanding the company's growth prospects.
See More
GeneDx Partners with Zevra to Enhance NPC Diagnosis and Treatment
- Genetic Testing Collaboration: GeneDx has partnered with Zevra Therapeutics to launch the ExomeDx genetic testing program aimed at expanding access for suspected Niemann-Pick disease type C patients, thereby accelerating clinical diagnosis and improving accuracy.
- Data-Driven Innovation: By leveraging the GeneDx Infinity dataset, the world's largest rare disease genomic dataset, partners can gain deeper insights into disease biology, thus accelerating the patient journey from diagnosis to treatment, showcasing the real-world impact of genomic insights.
- Strong Financial Performance: Zevra Therapeutics reported fourth-quarter earnings of $0.19 per share, exceeding analyst expectations of $0.05, with sales totaling $34.1 million, surpassing estimates of $28.1 million, indicating robust growth potential in the Niemann-Pick disease treatment sector.
- Strategic Shift: Zevra has relocated its global headquarters to Boston to better access specialized talent and plans to focus on multiple near-term growth opportunities in 2026, aiming to create greater value for the rare disease community and its shareholders.
See More
